Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search


Dopavision is a therapeutic company developing a digital therapeutic for myopia.

MyopiaX® is an application for smartphones that provides a treatment to slow the progression of myopia in children and adolescents. Used together with a virtual reality headset and a Bluetooth controller, MyopiaX® is an innovative, non-invasive method to control myopia that is portable, fun, and easy for children to use.

Use the MyopiaX® app to start a session, keep track of usage and performance to optimize treatment, customize daily availability, and much more. Each session with MyopiaX® delivers a light stimulus on top of the virtual reality game. The goal is to increase dopamine levels in the retina to slow the progression of myopia.


February 22, 2022
Dopavision presents new research at ARVO virtual conference - Dopavision
February 22, 2022
Dopavision featured in German TV magazine 3sat NANO - Dopavision
February 22, 2022
Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trials - Dopavision
July 16, 2021
Dopavision raises a $14,100,000 series A round.

Funding Rounds


Further Resources



Golden logo
By using this site, you agree to our Terms & Conditions.